SCHEDULE: Paradigm BioCapital Discloses 5.3% Stake in Lexeo Therapeutics

Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 5.3% of Lexeo Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Paradigm BioCapital Advisors LP, along with its affiliates Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., have filed a Schedule 13G.
• This filing indicates beneficial ownership of 4,175,382 shares of Lexeo Therapeutics, Inc. common stock.
• This ownership represents 5.3% of the total outstanding common stock.
• The reporting date for this ownership stake is June 30, 2026.
• The outstanding shares of common stock are based on Lexeo Therapeutics' Form 10-Q filed on May 11, 2026, which reported 78,521,634 shares outstanding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it reports a significant ownership stake but does not indicate any new strategic actions or performance updates.

Positives

• Significant ownership stake reported by Paradigm BioCapital, indicating confidence or strategic interest in Lexeo Therapeutics.
• The filing clearly delineates the reporting entities and their respective roles in the beneficial ownership.

Negatives

• The filing is a Schedule 13G, which is an informational filing and does not inherently signal new positive developments or performance improvements for the company.

Risks

• The filing does not explicitly mention any new risks or challenges.
• Potential for increased scrutiny or influence from a significant shareholder (Paradigm BioCapital) on company strategy or governance.

Future Outlook

This filing is a Schedule 13G and does not contain forward-looking statements or specific guidance regarding future performance.

Industry Context

StockSavvy.ai notes that significant ownership filings like this Schedule 13G are common in the biotechnology and pharmaceutical sectors, often indicating strategic investment or potential activist interest. Lexeo Therapeutics operates in the gene therapy space, a highly competitive and capital-intensive industry.

Stakeholder Impact

• Shareholders: May view the increased stake as a sign of investor confidence, potentially influencing stock price, or may anticipate future strategic moves by Paradigm BioCapital.
• Management: May need to engage with Paradigm BioCapital regarding their investment strategy and potential influence.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Paradigm BioCapital for any changes in ownership or strategic actions.
• Observe Lexeo Therapeutics' corporate developments and performance to understand the implications of this significant stake.

Key Dates

Keywords

Lexeo Therapeutics, Paradigm BioCapital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing